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Abstract 
Introduction: Depression often affects people suffering from serious illnesses, including 
oncological and palliative patients. It reduces their quality of life and worsens their prognosis. 
This is why it is so important to properly treat depression in palliative patients. 
 
Material and Methods: The information provided was collected as a result of analysis of 
various articles and textbooks on development, diagnosis and treatment, as well as prevention 
of depression in terminally ill patients using Google Scholar and PubMed databases.  
 
Results: The results show that  the most common drug in therapy for palliative patients with 
depression are the sluggish serotonin reuptake inhibitors (SSRIs). SSRIs inhibit serotonin 
transporter reducing serotonin reuptake. This raises the level of neurotransmitter - serotonin - 
in the synaptic cleft. They are well tolerated and have fewer side effects than older 
antidepressants (tricyclic antidepressants and monoamine oxidase inhibitors). Tricyclic 
antidepressants may relieve neuropathic pain and they are also beneficial for patients with 
insomnia. Mirtazapine in addition to antidepressant effects also causes increasing appetite, 
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reducing nausea and sedative effect. In cancer-diagnosed patients particular attention should 
be paid to side effects such as nausea and vomiting that may occur in patients undergoing 
radiotherapy and chemotherapy using SSRIs or TCAs. SSRI therapy have a good safety 
profile and also interacts less frequently, while atypical antipsychotics may reduce the 
discomforts of taking chemotherapy. An alternative method of treating depression is the use 
of psychostimulants such as methylphenidate. Another way to treat depression is 
psychotherapy. 
 
Conclusions: There are several options for treating depression in palliative patients. It is 
important to pay attention to the side effects of prescribed medicines. Nevertheless, the best 
results are obtained by combining pharmacotherapy with psychotherapy. 
 
Key words: depression, palliative patients, sluggish serotonin reuptake inhibitors, SSRI, 
tricyclic antidepressants, TCA 
  
Introduction  
 Depression is a disease with development resulting in a destructive effect on the entire 
body. The mentioned illness can affect people of all ages. However, those who suffer from 
serious diseases, including oncological and palliative patients, are particularly at risk. Patients 
with cancer and depression more often suffer physical symptoms. They experience worsening 
quality of life and more often have suicidal thoughts or a desire for accelerated death than 
cancer patients who do not have depression [1, 3]. 
 
Depression is not only associated with reduced quality of life and patients with 
depression have a worse prognosis, which is linked to shorter life expectancy, increased 
disability, longer hospitalization episodes. According to different accounts from 3.7% to 58% 
of palliative care patients suffer depression. The mentioned disease is therefore a common 
problem in terminal care, but often remains undiagnosed. Additionally, almost 80% of 
psychological disorders in severely ill patients are skipped in treatment. That is why, the 
treatment of these patients is commonly based only on the alleviation of physical symptoms, 
and mental disorders are overlooked [3]. 
 
One of the most important drawbacks of depression therapy in palliative treatment is 
very difficult diagnosis of this disorder among these patients. Numerous somatic symptoms 
that are included in the diagnostic criteria for major depression are simultaneously known as 
indications of advanced disease. The diagnosis must therefore be focused on psychological 
symptoms (hopelessness, worthlessness, unjustified guilt). Moreover, similar symptoms make 
it difficult to distinguish between real depression and sadness that accompanies the right 
illness. On the other hand, clinicians should also consider the diagnosis of other diseases that 
may also show a decreased mood (for example: hypothyroidism or Parkinson's disease) [2, 3, 
4]. 
The most common drug in therapy for palliative patients with depression are the 
sluggish serotonin reuptake inhibitors (SSRIs). SSRIs increase the level of neurotransmitter - 
serotonin - in the synaptic cleft, because it limits its reabsorption to the presynaptic cell. 
Unfortunately, the application of these drugs is also connected with numerous side effects. 
The attending physician should consider the harmful adverse effects of pharmacotherapy, 
adverse drug interactions and treatment-related problems that are inextricably linked to cancer 
therapy [1, 5]. 
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Psychotherapy, another modality for depression treatment in palliative patients, has no 
risk of side effects or drug interactions. The mentioned therapy is particularly useful for older 
patients who are already taking medicines for hypertension, diabetes and many more. 
Additionally, psychosocial sins can cause or worsen depressive episodes, so it is important to 
eliminate them. Moreover it may be very advantageous to treat depression in combination 
therapy, that is, using psychotherapy and medication [1]. 
  
Connection between terminal phase of the disease and depression 
Treatment of patients suffering from progressive diseases, with a limited life span, is 
often based on the treatment of physical symptoms. That is why psychiatric disorders are 
often overlooked and therefore 60-80% cases of depression are untreated. Some studies based 
on cancer patients reported prevalence of depression between 10 and 50%, the symptoms 
occur three times more often in the last 3 months before death than 1 year before [11]. 
 
 Individual emotional and behavioral reactivity patterns play a role in the development 
of major depressive disorders. Depression is a common condition in people receiving 
palliative care and it is not only associated with reduced quality of live [6, 11]. Those patients 
have poorer prognosis, poor treatment adherence, increased disability, longer inpatient 
episodes and shorter life expectancy [6, 8].  
 
In palliative care, a quick detection and diagnosis of depression is necessary to 
implement the appropriate treatment. Weakness and pain accompanying the disease, may 
cause difficulties and delay in diagnosis [6]. Similar symptoms make it difficult to distinguish 
depression from appropriate sadness in palliative care patients. There are also no diagnostic 
tests or biomarkers to facilitate the diagnosis [8]. Moreover, in order not to delay the 
implementation of appropriate treatment, clinicians should consider alternative diagnostics for 
other diseases that may be presented in a similar way, like dementia, hypothyroidism or 
Parkinson's disease. Therefore, it is important to carefully observe the palliative patient and be 
aware of non-verbal signs which may indicate depression, such as slumped posture, flat affect 
and reduced emotional reactivity [6]. 
 
 The suffering of palliative patients due to depression also applies to their caregivers, 
which reduces their quality of life and the risk of accelerating death [8]. Some studies show 
that fewer depressive symptoms and longer terminal patients' survival are associated with 
palliative care services [7].  
 
Family caregivers play an important role in palliative care, because at the end of life 
most patients in the terminal phase want to be cared for at home. In the case of palliative care 
patients at home, who are more tense and depressed at the end of their lives, the greater 
burden on family caregivers was observed. Care of a palliative patient, including 
psychological support and practical help, affects caregivers physically, socially and 
emotionally. They have to deal with fear or loss, they often lack sleep and therefore they feel 
tired and exhausted. Some studies showed that depression of the caregiver develops with the 
patient's depression and is more common in family caregivers than in a non-caregiving 
population [10]. It is likely that depression correlates with the severity of the disease, which 






SSRI as the first-line drugs 
Selective serotonin reuptake inhibitors (SSRIs) are usually chosen as first-line drugs in 
palliative care. It has been shown that in patients whose life expectancy is several months, 
these medicines are helpful and effective [12]. SSRIs include fluoxetine, fluvoxamine, 
setraline, paroxetine, citalopram and escitalopram. These drugs vary in strength and 
specificity of action on the serotonin transporter. Some of them, apart from inhibiting the 
serotonin transporter have additional pharmacological effects. They have different effects on 
hepatic enzyme CYP-450 which is important when the dosing and combination with other 
drugs [13, 14]. 
 
 It can take up to 4 to 6 weeks before their full clinical effect is seen [17].  They are 
well tolerated and have fewer side effects than older antidepressants like tricyclic 
antidepressants and monoamine oxidase inhibitors [12]. The most common side effects of 
SSRIs are nausea, decreased appetite, weight loss, sleep disorders and sexual dysfunction. 
The most serious complication is the serotoninergic syndrome (disturbances of consciousness, 
psychomotor stimulation, myoclonus, hyperthermia, sweating, chills, diarrhea, convulsions). 
Symptoms from the heart and circulatory system are rare compared to tricyclic 
antidepressants [15, 17, 19]. 
 
Fluoxetine is characterized by a very long duration of action, metabolites can work up 
to 14 days. It has potent inhibitory effects on hepatic enzymes especially CYP2D6 and 
CYP3A4. The starting dose is 5-10 mg/day, the dose can be increased to 60 mg/day. May 
have an impact on weight loss. [12, 13, 16, 17]. Fluvoxamine is a strong inhibitor of serotonin 
re-uptake. It is also a sigma receptor agonist, it may have a sedative effect. The half-life is 15 
hours. It inhibits enzymes CYP1A2 and CYP2C1 [16]. Paroxetine due to many interactions 
and stronger anticholinergic side effects is not recommended. There are also some reports of 
serious disorders liver function [13, 14, 16]. 
 
Sertraline, citalopram and escitalopram are characterized by a lower risk of enzyme 
inhibition.  Sertraline is generally well tolerated. The half-life is 26 hours. The starting dose is 
25 mg/day. Therapeutic daily dose is 50-200 mg [12, 14, 16]. Citalopram practically does not 
work on other transporters and receptors except for the serotoninergic transporter. It weakly 
inhibits CYP-450. It is used in doses 10-60 mg /day. Escitalopram is the (S)-stereoisomer of 
citalopram. Is the most selective of the available serotonin reuptake inhibitors. It has a faster 
duration of action than citalopram. The effectiveness of escitalopram in a dose 10-20 mg /day 
is comparable to a dose of 20-60 mg/day citalopram. This allows the recognition of 
escitalopram as a drug with a more favorable ratio of efficacy to tolerance [12, 18]. 
  
New antidepressants 
 There is no direct evidence from palliative care population indicating one group of 
antidepressants as the predominant one [23]. Based on several clinical trials, tricyclic 
antidepressants, mirtazapine and mianserin may replace SSRIs. 
Meta-analysis of 25 studies shows that as well SSRIs as TCAs were more efficacious 
than placebo, but before nine weeks of therapy the effect was statistically significant only for 
TCAs [20]. The anticholinergic effect that occurs during the use of TCA may be troublesome 
for geriatric patients and may include: constipation, dry mouth, urinary retention, orthostatic 




There is a lack of reliable data presenting the quality-of-life outcomes of TCAs, 
mirtazapine or mianserin therapy. In the referenced meta-analysis only 4 studies reported 
these outcomes. Although in all cases great improvement in measures of life quality was 
observed, different scales to assess these outcomes make results not readily comparable. 
Aside of efficacy and acceptability, other issues, dependent on the specific patient may impact 
upon choice of a drug. Among the palliative care population sedation and increased appetite, 
which are caused by mirtazapine, often are beneficial. Tricyclic antidepressants, such as 
amitriptyline, may relieve neuropathic pain. If a patient is already on a low dose of 
amitriptyline  for neuropathic pain, it may be beneficial to increase this dose, rather than 
introduce another antidepressant [20].  
 
According to a study by Lauren Rayner and co. [21] mirtazapine, sertraline and 
citalopram are considered to be a reasonable selection for use in palliative care patients. 
During TCAs therapy there is a greater risk in overdose than SSRIs, but they are potential 
second-line medicines, especially for a specific group of patients. In addition to their 
neuropathic pain reducing effect, this antidepressants may also be beneficial for patients with 
insomnia.  Additional mirtazapine effects, except increasing appetite, are:  early onset of 
action, reducing nausea and sedative effect what make it a reasonable therapy to try in an 
individual who is distressed by insomnia and weight loss [21]. Another very important 
advantage is the fact, that this medication has few significant drug interactions [22].  
 
 Antidepressants in cancer-diagnosed patients 
Depression in people diagnosed with cancer can be treated as a complication or a 
direct effect of  fighting against life-threatening disease. It may result from many factors, 
among which attention should be paid to the fight against chronic pain, fear of death, chronic 
stress related to the disease, metabolic, endocrine and immunological changes resulting from 
the disease itself as well as its treatment [25, 26]. 
 
A systematic analysis of 9 studies assessing the effectiveness of antidepressant therapy 
in cancer-diagnosed patients conducted by F. Matcham et al. in 2015 proved the lack of 
conclusive evidence confirming the effectiveness of antidepressants compared to placebo 
during 6-12 weeks of therapy. In addition, based on the analysis, it has not been possible to 
indicate which of the groups of medications used in the treatment of depression accepted by 
the patients showed a more favorable profile of effectiveness and tolerance [25].  
 
Therapy using commonly used drugs belonging to tricyclic antidepressants (TCAs) 
and selective serotonin reuptake inhibitors (SSRIs) is only supported by limited evidence [27]. 
Particular attention should be paid to side effects such as nausea and vomiting that may occur 
in patients undergoing radiotherapy and chemotherapy using SSRIs or TCAs [28]. However, 
available studies indicate that SSRI therapy such as escitalopram, citalopram, and setraline 
have a good safety profile and also interact less frequently, while atypical antipsychotics such 
as quetiapine and olanzapine may reduce the discomforts of taking chemotherapy [28]. 
 
  In the case of oncological patients, drugs interactions are particularly important 
because anti-cancer drugs are mostly characterized by a narrow therapeutic range, so any 
change in their concentration in the blood due to drug interactions may lead to therapeutic 
failure - for example, patients with breast cancer treated with tamoxifen. In this group, 
antidepressants that are also an inhibitor of CYP2D6 should be avoided because inhibition of 
this enzyme results in the decrease of concentration of endoxifene (the active metabolite of 
tamoxifen), thus increasing the risk of relapse [29, 30]. 
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In the case of the patients with cancer or in terminal phase,  anti-depression treatment 
is different. It is better to avoid typical antidepressants due to  therapy based on regression of 
symptoms. In such cases, the alternative seems to be ketamine, also used in pain therapy, due 
to the NMDA receptor involved in the pathophysiology of chronic pain [26, 31]. However, to 
confirm the effectiveness of ketamine as an antidepressant in terminal cancer-diagnosed 
patients, multi-center randomized clinical trials are required. 
 
Among other alternative treatments of depression, terminally ill patients also use 
psychostimulants such as methylphenidate. In 1996, Jonathan Olin and Prakash Masand 
carried out a study to analyze the history of the disease of oncological patients with 
depression treated with dextroamphetamine or methylphenidate. An improvement was noted 
after only 2 days of treatment, 83% of patients showed some improvement in depressive 
symptoms, while 73% of all patients showed a significant or moderate improvement. There 
were no differences in efficacy between the used drugs. Based on this study, conclusions were 
drawn that it is a safe and effective therapy. However, it should be noted that in the case of 
psychostimulants, the physiological tolerance increases rapidly, which in turn is associated 
with increasing the dose of the drug [26, 32]. 
 
Pharmacotherapy vs psychological therapy  
The prevalence of depression is particularly high in elderly patients [33]. There are 
several ways of treating depression including antidepressant medications and different types 
of psychotherapy. The treatment may also combine psychotherapy and pharmacotherapy. 
They both have their advantages and disadvantages. 
 
Pharmacotherapy may be based on a variety of drugs which mechanisms mainly 
impact the concentration of neurotransmitters in central nervous system. SSRIs are the first-
line treatment and the most often choice [34]. In the past, older classes of antidepressants 
were used, such as: tricyclic antidepressants and monoamine oxidase inhibitors. The usage of 
SSRIs is constantly increasing and older agents are replaced by them [34]. Studies have 
proven that SSRIs are as effective as older antidepressants with the only exception of 
amitriptyline which has stronger effect. Moreover, they are more tolerable in comparison to 
TCAs [37]. What is most important, SSRIs cause less antimuscarinic side effects but more 
gastrointestinal ones. Newer agents such as SSRIs cause fewer side effects in comparison to 
older ones. Despite many advantages pharmacotherapy may fail in patients who are not 
willing to undergo such treatment or are susceptible to side effects or interactions between 
drugs [34]. 
 
There are many psychotherapies of depression and the most common of them is 
cognitive behaviour therapy. Psychotherapy has its advantages – there is no risk of side 
effects, or drug-drug interactions [34]. It is important for older, geriatric patients who suffer 
from other conditions, for instance diabetes mellitus [35], other general diseases and are prone 
to drug interactions. Considering that psychosocial stressors may cause or worsen depressive 
episodes, psychotherapy may help develop abilities of interpersonal interactions, dealing with 
stressors, and improve social supports [34]. The disadvantage of psychotherapy alone may be 
its late response. Moreover, patients may meet many structural obstacles – higher costs of 




Metaanalysis from 2017 showed that pharmacotherapy and psychotherapy have equal 
effects – that is the improvement of functioning and better quality of life [37]. The 
combination of pharmacotherapy and psychotherapy gives significant effects in comparison to 
each method of treatment alone. Nevertheless, each therapy alone is also efficacious for 
treating depression [37]. Another study indicated that the result of treatment may vary in a 
significant way depending on the choice of antidepressant or psychotherapy [38].  
 
Discussion  
In the first part of results there was described connection between terminal phase of 
the disease and depression. It is worth mentioning that the occurrence of depression in the 
group of end-of-life patients is estimated at approximately 20 to over 50%, moreover it 
especially affects patients with advanced metastatic processes also the ones with neck, head 
and pancreatic tumors [39, 40]. According to the statistics besides cancers the most common 
somatic diseases accompanying depression are: Parkinson’s disease (51%), pain syndromes 
(50%), brain stroke (23-35%), Alzheimer’s disease (11%) [41].  
  
            Furthermore, there was a part about SSRI (selective serotonin reuptake inhibitor) used 
as the first-line drugs in depression in palliative care. Fluoxetine, fluvoxamine, paroxetine, 
sertraline, citalopram, escitaloporam were mentioned in this part of work. In section about 
antidepressants in cancer-diagnosed patients an author mentioned about TCAs (tricyclic 
antidepressants). Additionally, in neuropathic pain associated with tumors some 
antidepressants for example duloxetine, venflaxine and tricyclic antidepressants are 
commonly used. All of the mentioned drugs in last sentenced are classified as SNRIs 
(serotonin-norepinephrine reuptake inhibitors). In the treatment of neuropathic pain daily dose 
100 mg is not exceeded, moreover in the group of patients older than 65 years daily dose 
greater than 75 mg is not recommended [42, 43]. 
  
            Last but not least, beside dementia, depression is the most common mental disorder in 
elder people. According to various authors, the incidence of depression among people over 65 
years life is 2.4-11.3%, while psychotic depression is 1-3,7% of the elderly population [44, 
45]. It is often unrecognized and untreated disorder, and its symptoms are treated as part of 
the natural aging process or the consequence of somatic illness. Patients with depression are 
frequently terminally ill. As proven, mortality in the elderly population with depression is 
greater than in the population of people without depression [46]. 
 
Conclusions 
Depression is a common disease that can affect everyone, but palliative patients at 
more at risk. Because of chronic disease that cause pain, sleepless nights, days spend at a 
hospital and a lack of will to live those patients often develop depression. Unfortunately, 
psychological issues are underestimated and only physical symptoms are treated.  
  
Depression  can be hard to diagnose in palliative patients, but it should always be 
taken into consideration. They often suffer from malignant cancer,  their life is expected to be 
shorter and its quality is lower because of the disability and constant negative thoughts. It is 
important to think about other diseases with similar symptoms like hypothyroidism or 
neurological issues. Thorough observation and talking to the patient is crucial. What is 




The basic of pharmacotherapy are SSRI, like sertraline or fluoxetine. They are 
effective, safe and so commonly used as first-line drugs.  Like every medicine they can cause 
side effects, like nausea or insomnia, though they are believed to be much less harmful to the 
cardiovascular system than tricyclic antidepressants.  Doctors should remember about 
serotoninergic syndrome when prescribing other drugs to the patient taking SSRI that may 
affect serotonine levels. 
  
TCA can be more effective in palliative patients than SSRI, although they lead to 
anticholinergic side effects that can negatively influence elderly ones so the dose should be 
controlled.  Amitryptyline can be good in reducing neuropathic pain. Different kind of drug –
mirtazapine- can be helpful in insomnia and lack of appetite cases. New antidepressants can 
be useful when SSRI do not give expected effects. 
  
Depression often appears in cancer-diagnosed patients but is underrated because 
doctors do not want to focus on it. Studies did not prove enough efficiency of SSRI or TCA in 
those group of people, but they may be helpful in some cases. Attention should be paid to 
interactions between antidepressants and ongoing treatment to not cause negative 
effects.  Atypical antipsychotics like ketamine seem to have a potential, but more research is 
needed. Methylphenidate can also be effective in oncological patients with depression. 
  
Pharmacotherapy can be efficient in treating depression in terminally ill patients, but 
there is always a risk of side effects and interactions. Psychotherapy is completely safe and 
resultful but more time is needed for response. Cognitive behavior therapy is the most 
common and helps patients deal with their negative thoughts. Medication and psychotherapy 
used in combination give significant results. 
  
Treatment of depression in palliative patients is an essential but overlooked issue. It is 
still being investigated  and  more research about new antidepressants and psychological 
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